BioTuesdays

Category - Markets

Markets

Piper upgrades Nuvectra to OW; PT to $16

Piper Jaffray upgraded Nuvectra (NASDAQ:NVTR) to “overweight” from “neutral” and raised its price target to $16 from $12 after the company reported fourth quarter results. The stock closed at $11.69 on March 15. The...

March 16, 2018
Volition
Markets

VolitionRx closes $8.4-million stock offering

VolitionRx (NYSE American:VNRX) closed an offering of 3.5 million common shares at a price of $2.40 a share for gross proceeds of $8.4-million. Volition, which develops blood tests to help diagnose a range of cancers...

March 14, 2018
Motus GI Holdings
Markets

Piper starts Motus GI at OW; PT $7

Piper Jaffray initiated coverage of Motus GI Holdings (NASDAQ:MOTS) with an “overweight” rating and $7 price target. The stock closed at $4.98 on March 9. The company’s Pure-Vu device makes the prep regimen for...

March 12, 2018
Can-Fite
Markets

Maxim cuts Can-Fite Biopharma to hold; removes PT

Maxim Group downgraded Can-Fite Biopharma (NYSE American:CANF) to “hold” from “buy” and removed its previous $7 price target after the company announced a $5-million registered direct offering. The stock was quoted at...

March 9, 2018
Juniper Pharmaceuticals
Markets

Roth doubles Juniper Pharma PT to $24

Roth Capital Partners doubled its price target for Juniper Pharmaceuticals (NASDAQ:JNP) to $24 from $12 after the company reported 2017 results. The stock closed at $10 on March 9. Juniper is focused on developing...

March 9, 2018
Myomo
Markets

Roth starts Myomo at buy; PT $9

Roth Capital Partners initiated coverage of Myomo (NYSE American:MYO) with a “buy” rating and $9 price target. The stock closed at $4.15 on March 8. Analyst Scott Henry writes that the MyoPro robotic arm brace offers...

March 9, 2018
Dicerna Logo
Markets

Stifel ups Dicerna Pharma PT to $17 from $10

Stifel raised its price target for Dicerna Pharmaceuticals (NASDAQ:DRNA) to $17 from $10 after the company reported fourth quarter results. The stock closed at $13.50 on March 18. Dicerna is a leading developer of...

March 9, 2018
American Renal
Markets

Leerink cuts American Renal to MP but ups PT to $27

Leerink downgraded American Renal Associates (NYSE:ARA) to “market perform” but raised its price target to $27 from $17, citing a fuller valuation after the company reported fourth quarter results. The stock closed at...

March 8, 2018